TG Therapeutics Inc (NASDAQ:TGTX)’s traded shares stood at 3.27 million during the last session, with the company’s beta value hitting 2.20. At the close of trading, the stock’s price was $29.54, to imply a decrease of -4.23% or -$1.3 in intraday trading. The TGTX share’s 52-week high remains $36.50, putting it -23.56% down since that peak but still an impressive 63.37% since price per share fell to its 52-week low of $10.82. The company has a valuation of $4.60B, with an average of 5.61 million shares in intraday trading volume over the past 10 days and average of 3.84 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for TG Therapeutics Inc (TGTX), translating to a mean rating of 1.50. Of 6 analyst(s) looking at the stock, 0 analyst(s) give TGTX a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 5 recommend it as a Buy.
TG Therapeutics Inc (NASDAQ:TGTX) trade information
After registering a -4.23% downside in the last session, TG Therapeutics Inc (TGTX) has traded red over the past five days. The 5-day price performance for the stock is 2.53%, and 23.39% over 30 days. With these gigs, the year-to-date price performance is 72.95%. Short interest in TG Therapeutics Inc (NASDAQ:TGTX) saw shorts transact 32.0 million shares and set a 13.37 days time to cover.
The extremes give us $16 and $55 for target low and target high price respectively. As such, TGTX has been trading -86.19% off suggested target high and 45.84% from its likely low.
TG Therapeutics Inc (TGTX) estimates and forecasts
Looking at statistics comparing TG Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. TG Therapeutics Inc (TGTX) shares are 79.25% up over the last 6 months, with its year-to-date growth rate higher than industry average at 88.89% against 11.80%.
TGTX Dividends
TG Therapeutics Inc has its next earnings report out on 2025-Feb-26. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders
TG Therapeutics Inc insiders hold 9.50% of total outstanding shares, with institutional holders owning 66.32% of the shares at 73.29% float percentage. In total, 66.32% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 13.69 million shares (or 9.3645% of shares), all amounting to roughly $243.58 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 11.39 million shares, or about 7.7891% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $202.6 million.
